Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9%Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The "Blood ...

Inc. dba AIBotics (“AIBotics” or the “Company”) (OTC: TPIA) and a wholly owned subsidiary of Ehave (OTC: EHVVF), a developer and manager of companies and technologies that can be enhanced through ...

Highlighting their involvement at Manifest 2025, Bob Reny, Dot Ai's CRO, and Jeff Schmitt, COO of Würth Industry USA, a division of WINA, will be in attendance and will co-moderate a thought-provoking ...

The Company continues to work diligently to file the required report by May 14, 2025.

Hurlston is a proven technology executive with over 30 years of senior leadership experience within the industry. He joins Lumentum from Synaptics, Inc., a worldwide pioneer and leader in human ...

ServiceNow, Chevron, Exxon Mobil, GE Vernova, Constellation Energy, EnLink Midstream, and AltC Acquisition are the seven Oil stocks to watch today, according to MarketBeat’s stock screener tool. Oil ...

Changes under Customs, Excise & Service Tax. CHANGES IN CUSTOMS. The Finance Minister introduced the Finance Bill, 2025 in Lok Sabha tod ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

Instructions Orders Press Release Budget 2025 Budget 2024 Budget 2023 Budget 2022 Articles News Judiciary ...

Carbon Revolution plc (Nasdaq: CREV) (the "Company"), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...